Previous Close | 27.25 |
Open | 27.27 |
Bid | 26.90 x 100 |
Ask | 26.99 x 100 |
Day's Range | 26.63 - 27.30 |
52 Week Range | 14.89 - 32.53 |
Volume | |
Avg. Volume | 730,367 |
Market Cap | 2.438B |
Beta (5Y Monthly) | 1.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.92 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.36 |
Subscribe to Yahoo Finance Plus to view Fair Value for RCKT
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRANBURY, N.J., March 26, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Aaron Ondrey, as Chief Financial Officer, and the further evolution of its corporate leadership team through key appointments with existing team members. These leadership announcements build on and expand Rocket’s preparedness for its plann
Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.